Abivax Denies Acquisition Speculation Involving AstraZeneca

The French biotechnology firm Abivax has issued a firm denial regarding reports of an imminent takeover by pharmaceutical giant AstraZeneca. The company’s statement on Thursday was a direct response to market rumors suggesting an exclusive due diligence period was nearing its conclusion, potentially leading to a formal offer.

Focus Remains on Clinical Asset

At the heart of the persistent market interest in Abivax is its lead drug candidate, Obefazimod. The potential treatment for ulcerative colitis is currently undergoing pivotal Phase 3 clinical trials. The scientific significance of this program was recently highlighted at the ECCO 2026 conference, where Abivax presented a total of 22 abstracts related to the compound. Industry attention is particularly drawn to data indicating anti-fibrotic effects, which suggest the therapy’s potential could extend to other chronic inflammatory diseases.

This is not the first instance of takeover rumors surrounding the company. Similar speculation emerged in December 2025 concerning potential interest from U.S.-based Eli Lilly, which management dismissed as “noise” at the time.

Should investors sell immediately? Or is it worth buying Abivax?

Report Sparks Market Speculation

The latest round of speculation was triggered by a report from the French publication La Lettre. According to the report, Abivax had granted AstraZeneca exclusive access to confidential company data. This arrangement was allegedly set to run until March 23, 2026, a move that would have positioned the British-Swedish conglomerate as the clear frontrunner in any potential bidding process.

The report further suggested that if a formal offer were not made by the deadline, other interested parties, such as Eli Lilly, could re-enter the process. It was also noted that the French Finance Ministry is closely monitoring developments due to Abivax’s strategic importance within the healthcare sector.

Clarity Awaited

The official denial from Abivax has temporarily eased the speculative pressure in the market. Definitive clarity on the situation is expected when the speculated deadline of March 23 passes. Should AstraZeneca not take action by that date, market participants are likely to refocus their attention squarely on the clinical progress of the Obefazimod development pipeline.